Related Experiment Videos
Enalapril in the treatment of congestive heart failure
1Department of Medicine, Tulane Medical School, New Orleans, Louisiana.
Insights
Enalapril, an ACE inhibitor, improves heart function and exercise capacity in congestive heart failure patients. This treatment also reduced heart size and mortality in severe cases.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Congestive heart failure (CHF) affects 1% of the U.S. population.
- Pathophysiology involves systemic vasoconstriction and fluid retention, worsening cardiac workload.
- Neurohumoral mechanisms exacerbate CHF progression.
Purpose of the Study:
- To evaluate the efficacy of enalapril, an angiotensin converting enzyme (ACE) inhibitor, in managing congestive heart failure.
- To assess enalapril's impact on hemodynamic parameters and functional capacity in CHF patients.
Main Methods:
- Administration of enalapril, a long-acting ACE inhibitor.
- Assessment of New York Heart Association (NYHA) functional class.
- Measurement of pulmonary capillary wedge pressure and cardiac index.
- Evaluation of maximum oxygen uptake and exercise tolerance.
Main Results:
- Enalapril improved NYHA functional class, pulmonary capillary wedge pressure, cardiac index, maximum oxygen uptake, and exercise tolerance.
- In severe CHF patients, enalapril treatment led to reduced heart size.
- Patients treated with enalapril required less additional heart-failure medication.
- Enalapril demonstrated a reduction in mortality rates for severe CHF patients.
Conclusions:
- Enalapril effectively interrupts CHF pathophysiology by improving hemodynamics.
- Long-term enalapril treatment offers significant benefits for CHF patients, including improved functional capacity and reduced mortality.
- Enalapril is a valuable therapeutic option for managing congestive heart failure, particularly in severe cases.
Abstract:
Congestive heart failure (CHF) is a complex clinical syndrome affecting 1% of the U.S. population. The basic dysfunction, a lack of sufficient blood flow to the periphery, triggers reflex neurohumoral mechanisms that cause systemic vasoconstriction and sodium and water retention as the body attempts to protect vital organs. This, in turn, results in additional work for the failing heart and further deterioration. Vasodilators, in general, and angiotensin converting enzyme (ACE) inhibitors, in particular, interrupt this pathophysiology and improve hemodynamics. Enalapril, a long-acting ACE inhibitor, has been demonstrated to improve New York Heart Association (NYHA) functional class, pulmonary capillary wedge pressure, cardiac index, maximum oxygen uptake, and exercise tolerance in CHF patients. Data from a recent trial provide evidence that a group of patients with severe CHF who were treated with enalapril showed reduced heart size, reduced need for other heart-failure medication, and reduced mortality.